Development of an adjuvant active nonionic block copolymer for use in oil-free subunit vaccines formulations

被引:30
作者
Todd, CW
Pozzi, LAM
Guarnaccia, JR
Balasubramanian, M
Henk, WG
Younger, LE
Newman, MJ
机构
[1] CYTRX CORP,NORCROSS,GA 30092
[2] LOUISIANA STATE UNIV,SCH VET MED,VAN,BATON ROUGE,LA 70803
关键词
adjuvant; copolymer; CRL1995; vaccine;
D O I
10.1016/S0264-410X(97)00209-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nonionic block copolymers, synthesized from repeating units of oxypropylene and oxyethylene, can be designed so that individual copolymers have unique physical properties with differential levels of adjuvant activity. We have designed high molecular weight block copolymers that spontaneously assemble into 500 nm-3 mu m particles when formulated with protein antigens in aqueous solutions at physiological pH. The adjuvant activity of one of these copolymers, termed CRL1005, was compared to selected research adjuvants using ovalbumin (OVA) as the prototype vaccine antigen. Suboptimal doses of OVA were formulated with complete and incomplete Freund's adjuvant (CFA/IFA), alum, Quil-A saponins, Ribi Adjuvant System (RAS) or the CRL1005 copolymer and these formulations were used to immunize C57BL/6 mice. The CRL1005 copolymer appeared to be more potent than either Quil-A or alum and comparable to the RAS formulation, based on the numbers of responding mice and the OVA-specific antibody titers. Alum, RAS and Quil-A all augmented the production of IgG(1) and IgG(2b) similarly whereas only the CFA/IFA boosted IgG(2a) levels significantly. The effect of adjuvants on relative antibody affinity was more variable with the CRL1005 and CFA/IFA inducing antibodies with the highest affinity scores. This high molecular weight nonionic copolymer is nontoxic in aqueous formulations and should therefore be compatible with a wide variety of protein or polysaccharide vaccine antigens. (C) 1997 Published by Elsevier Science Ltd.
引用
收藏
页码:564 / 570
页数:7
相关论文
共 47 条
  • [31] PHASE-1 TRIAL OF IMMUNOLOGICAL ADJUVANT QS-21 WITH A GM2 GANGLIOSIDE-KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE IN PATIENTS WITH MALIGNANT-MELANOMA
    LIVINGSTON, PO
    ADLURI, S
    HELLING, F
    YAO, TJ
    KENSIL, CR
    NEWMAN, MJ
    MARCIANI, D
    [J]. VACCINE, 1994, 12 (14) : 1275 - 1280
  • [32] THE MEASUREMENT OF RELATIVE ANTIBODY-AFFINITY BY ELISA USING THIOCYANATE ELUTION
    MACDONALD, RA
    HOSKING, CS
    JONES, CL
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 106 (02) : 191 - 194
  • [33] IMMUNIZATION OF BREAST-CANCER PATIENTS USING A SYNTHETIC SIALYL-TN GLYCOCONJUGATE PLUS DETOX ADJUVANT
    MACLEAN, GD
    REDDISH, M
    KOGANTY, RR
    WONG, T
    GANDHI, S
    SMOLENSKI, M
    SAMUEL, J
    NABHOLTZ, JM
    LONGENECKER, BM
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (04) : 215 - 222
  • [34] McKercher P. D., 1986, Advances in carriers and adjuvants for veterinary biologics, P115
  • [35] MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145
  • [36] RECOMBINANT CYTOKINES AS IMMUNOLOGICAL ADJUVANTS
    NASH, AD
    LOFTHOUSE, SA
    BARCHAM, GJ
    JACOBS, HJ
    ASHMAN, K
    MEEUSEN, ENT
    BRANDON, MR
    ANDREWS, AE
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 1993, 71 : 367 - 379
  • [37] CYTOKINES AS POTENTIAL VACCINE ADJUVANTS
    NOHRIA, A
    RUBIN, RH
    [J]. BIOTHERAPY, 1994, 7 (3-4) : 261 - 269
  • [38] PAYNE LG, 1995, VACCINE DESIGN SUBUN, P473
  • [39] REDDISH MA, 1995, ONKOLOGIE, V18, P33
  • [40] RUDBACH JA, 1995, THEORY PRACTICAL APP, P287